


Calistoga Pharmaceuticals
Biotechnology Research • Seattle, Washington, United States • 1-10 Employees
Company overview
| Headquarters | 2101 Fourth Ave, suite 1960, Seattle, Washington 98121, US |
| Phone number | +107804443213 |
| Founded | 2006 |
| Employees | 1-10 |
| Socials |
Key Contact at Calistoga Pharmaceuticals
Mike Gallatin
President
About Calistoga Pharmaceuticals
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Calistoga Pharmaceuticals revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | $40,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Explore Calistoga Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Frequently asked questions
4.8
40,000 users



